Dr. Michael Plazak and CardioScripts co-host, Dr. Tracy Macaulay, discuss the DOREMI trial.
0:00-0:25: Introduction
0:26-0:53: Introduction of Dr. Michael Plazak
0:54-3:29: DOREMI Overview
3:30-4:58: Overview of Milrinone vs Dobutamine pharmacokinetics and historic considerations
4:59-6:08: Overview of SCAI Classification of Cardiogenic Shock
6:09-10:09: Overall Thoughts on the DOREMI Trial
10:10-13:22: Baseline Beta-Blocker Use and Subgroup Analysis
13:23-15:09: Impact on Clinical Practice
15:10-16:34: Cost Considerations
16:35-17:44: Closing
References:
DOREMI: Mathew R, Di Santo P, Jung RG, et al. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. N Engl J Med. 2021;385(6):516-525. doi:10.1056/NEJMoa2026845
Baseline Beta-Blocker use in DOREMI: Subgroup Analysis: Di Santo P, Mathew R, Jung RG, et al. Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial. Crit Care. 2021;25(1):289. Published 2021 Aug 10. doi:10.1186/s13054-021-03706-2
Metra M, Nodari S, D’Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002;40(7):1248-1258. doi:10.1016/s0735-1097(02)02134-4
